About Us

Mission

image1

  • CureImmune is an innovative biopharmaceutical company focused on the development of therapeutic agents for cancer and immunological disorders by targeting key regulators of the immune system. Our technology platform consists of proprietary monoclonal antibodies, fusion proteins and bifunctional agents.  

Leadership

image2

Management

  • Yiwen Li, MD, Chief Scientific Officer, Board Member
  • Yuxiang Hu, MD, VP of Research, Board Member
  • Guangming He, Chairman of the Board



Scientific Advisory Board

  •  Lieping Chen, MD, PhD,  Scientific Advisor; UTC Professor in Cancer Research, Immunobiology, and Medical Oncology at the Yale School of Medicine 

Pipeline

image3

_______________________________________ Candidate        Type           Status           Indication ________________________________________ CIT-100       Antibody        Pre-clinical       Cancer   CIT-801       Bifunctional   Pre-clinical      Cancer         CIT-802       Bifunctional   Pre-clinical      Cancer       ______________________________________